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I ¢ERIMENTAL NEUROLOGY 124, 289-298 (1993)

jJ-Amyloid of Alzheimer's Disease Induces Reactive Gliosis
That Inhibits Axonal Outgrowth
DAVIDR. CANNING,* ROBERTJ. MCKEON,* DAVIDA. DEWITT,* GEORGEPERRY,t
JEROME R. WUJEK,:!: R. C. A. FREDERICKSON,:j: AND JERRY SILVER*
Departments of *Neurosciences and t Pathology, Case Western Reserve University, School of Medicine, 10900 Euclid Avenue,
Cleveland, Ohio 44106-4975; and :j:Gliatech, Inc., 23420 Commerce Park Road, Cleveland, Ohio 44122
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Pathological lesions in the brains of patients with
Alzheimer's disease (AD) are characterized by dense deposits of the protein ,B-amyloid. The link between the
deposition of ,B-amyloid in senile plaques and AD-associated pathology is, at present, controversial since
there have been conflicting reports on whether the 3943 amino acid ,B-amyloid sequence is toxic or trophic to
neurons. In this report, we show that ,8-amyloid peptide
when presented as an insoluble substrate which mimics
its conformation in vivo can induce cortical glial cells in
vitro and in vivo to locally deposit chondroitin sulfate
containingproteoglycan. In vitro the proteoglycan-containing matrix deposited by glia on ,8-amyloid blocks the
usual ability of the peptide to allow cortical neurons to
adhere and grow. Chondroitin sulfate-containing proteoglycan was also found in senile plaques of human AD
tissue. We suggest that an additional effect of ,8-amyloid
in the brain, which compounds the direct effects of ,8amyloid on neurons, is mediated by the stimulation of
astroglia to become reactive. Once in the reactive state,
glial cells deposit large amounts of growth-inhibitory
molecules within the neuropil which could impair neuronal process survival and regeneration leading to neurite retraction and/or dystrophy around senile plaques
in AD. © 1993 Academic Press, Inc.

INTRODUCTION

Astrogliosis is a classic hallmark of trauma and disease of the central nervous system (5, 6). It is believed
that the role of gliosis in the adult is to wall off the area
of injury which, in turn, prevents local regeneration of
neuronal processes (25). Recently, a molecular component associated with the extracellular matrix of astroglial scars following trauma has been shown to be a
c~ondroitin-6-sulfate-containing proteoglycan (21). In
lnVD; this proteoglycan, found in the adult cortex, colo~alizes with intensely GFAP-positive astrocytes in and
llll:rnediately adjacent to induced scars, but not with
other GFAP-positive astrocytes distant from the injury

site (21). Neurons fail to elaborate axons in vitro on the
surface of scars removed intact from adults, unless the
glycosaminoglycan chains are digested with chondroitinase, suggesting that chondroitin sulfate-containing
proteoglycan deposition may be involved in limiting the
growth of regenerating axons in the CNS (22). This idea
is supported by the finding that certain proteoglycans
found during development have been shown to be regulatory to axonal outgrowth. For instance a chondroitin
sulfate/keratan sulfate-containing proteoglycan, located on astrocytes in boundary regions of the developing embryo, limits axon elongation in vitro (7, 32) and a
chondroitinase-sensitive proteoglycan regulates the
patterning ofaxons in the retina (4).
Apart from trauma, gliosis may be a normal consequence of senescence in the brain and especially in
neurodegenerative diseases, where there is an increase
in reactive glia in response to failing CNS mechanisms
(9,12, 18, 26). Accordingly, astrogliosis could playa fundamental role in the development of pathological lesions in Alzheimer's disease (AD) (10). In the AD brain,
reactive astrocytes are found in high abundance around
molecularly heterogenous cores of IJ-amyloid found
within senile plaques (9, 12, 13,23). Also, the presence
of various sulfated proteoglycans in association with
amyloid fibrils (29, 30, 31, 37) suggests that reactive
gliosis could contribute specified extracellular matrix
components to the forming IJ-amyloid aggregate. Indeed, the plaque-related glial interactions may be triggered by the deposition of IJ-amyloid (19) and might represent an attempt to wall off the IJ-amyloid core.
Neither the source of plaque-associated proteoglycans nor the effect these molecules have on neuronal
survival or neurite dystrophy in AD are known. In this
report, we have investigated the hypothesis that neurite
retraction or neuronal death in the AD brain is a consequence of secondary cellular reactions in the form of a
functionally reactive gliosis, triggered by insoluble 1-40
and 25-35 peptide fragments of IJ-amyloid variously reported to be neurotoxic (see the complete issue of N eurobiol. Aging 13(5) for up-to-date review). This reactive
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gliosis, we propose, leads to the deposition of inhibitory
molecules which are severely adverse to neuronal process survival.
METHODS

In Vitro Spot Assay

I

:1

For preparation of substrates for the spot assays, 0.51 ,ul of a 2 roM solution of (J-amyloid peptides (1-40 and
25-35 amino acids were obtained from Bachem California Inc., scrambled 25-35 and scrambled 1-40 kindly
donated by Gliatech, Inc.) were allowed to air-dry under
sterile conditions onto nitrocellulose-coated 35-mm petri dishes or Flaskette chambers (for time-lapse videomicroscopy). This produced peptide spots in the range
of 0.7-1.2 mm in diameter which visibly adhered to the
surface of the dish and persisted for the duration of the
experiments (confirmed by ponceau S staining of peptide). Prior to seeding cells, substrates were overlayed
with a 5 ,ug/ml solution of laminin in calcium-magnesium-free Hanks' balanced salt solution (CMF).

Culture of Cortical Neurons
Cortical neurons were obtained from Embryonic Day
16 rat embryos. Following removal of fetuses from the
mother, cerebral cortices were removed into CMF and
cut into small pieces and trypsinized for 10 min at 37°C.
Following the addition of DMEM-F12 supplemented
with 10% FCS, cells were resuspended to a determined
cell density and plated onto prepared peptide spot substrates. For seeding onto conditioned spots, glial cells
were first removed from the dishes after 2-14 days by
extensive washes with sterile distilled water, after which
cortical neurons were seeded as above.

Filter Implant Assay
For testing the in vivo response to (J-amyloid peptides,
pieces of Millipore filter either impregnated with (Jamyloid peptide (n = 10) or saline (control; n = 10) were
implanted into the cerebral cortex of neonatal rats.
Briefly, both groups of PO animals were anesthetized on
ice. An incision was made on the dorsal surface of the
head and the skin was retracted. The skull was cleaned
of the periosteum and a small rectangular opening made
through the skull. Next, a 2 X 2-mm piece of sterile
nitrocellulose filter (Millipore Corp.) was implanted
into the cerebral cortex, and the incision was closed.
After 30 days animals were anesthetized with chloral
hydrate and perfused with 4 % paraformaldehyde. The
brains were postfixed for 4 h in the same fixative and
then cryoprotected with sucrose prior to cryostat sectioning and staining for the presence of chondroitin sulfate-containing proteoglycan. Sections from the brains
of these animals were also stained for the presence of

(J-amyloid (antibody kindly provided by 'G. Perry)
showed that (J-amyloid does not noticeably dissi and
over the 30-day time period, remaining in the Milll Pate
filters.
POre

Culture of Glial Cells
Glial cel.ls were obtained.from PO-P2 neonatal rats b
the followmg method. Brams were dissected into Cl\1~
and then left and right cerebral cortices were freed
·
surroun di ng t Issue
an d
cut'mto small (0.5 mm) pie ~
.
.
1
ces
·
"
tD ISSO.cI~~lOn(Omto :)mg e ?ells was achieved by briefi;
rypsmIzmg .25"/0 the tIssue and passing it through:
Nitex filter (60 ,um). The cell suspension was th a·
seeded into Falcon tissue culture flasks in DMEl\1-F~~
supplemented with 10% FCS. After 3 days, nonadherent
cells were lightly shaken off and the medium was
changed. Before the cells became confluent, adherent
cells were passaged into fresh flasks by trypsinizatio
(0.25%) for 15 min at 37°C and replated in DMEM-FI~
supplemented with 10% FCS. Under these conditions
approximately 95% of the cells were found to be GFAP
positive. At this point some cultures were incubated
with a small volume (1 ,ulIO ml- 1 ) of 0.06-,um Fluoresbri~e carboxy~ate microspheres (Polysciences Inc.)
WhICh are readily phagocytosed by glial cells and allows
identification of cells on phase opaque substrates with
fluorescent optics. Cells were passaged an additional
two times before use in the substrate assays. For seeding
onto peptides in the spot assays, glial cells were removed from these cultures following a similar trypsinization protocol, resupended to a determined concentration, and plated onto prepared peptide substrates (as
described above).

Timelapse Video microscopy
Once seeded with glia or neurons, time-lapse videomicroscopy was performed on selected cultures using an
inverted Zeiss microscope at various magnifications.
Time-lapsed cultures were maintained at 37°C for up to
3 days with a thermostatically controlled heated air
blower and filmed using a Hamamatsu CCD camera.
Films were made of cells on and off the (J-amyloid spots
after differing times postseeding (from Time 0 to 14
days postseeding). Under either Nomarski or phasecontrast optics, images were taken every 100-360 s using a MetelTek shutter control system operated by an
Image 1 system. Digitized images were averaged, contrast-enhanced where required, and stored on a Pansonic LF 7010 optical disc recorder. Selected videoprints
were made from stored images with a Sony 500- W video
printer.

Immunohistochemistry
For immunocytochemistry, cultures were briefly
rinsed in PBS and fixed for 12 h at 4°C with 4% formal

(

I
\

j
\
)
)
)

'-~

•

~

-

~~-.- ,~q

'"

,i

~J;-." ..."""""" .. ~...' ~, ...r_l'.r.': ''\:'~'''''~J1~<".!L'1.I-~";j~-r.>tf~~Cl:':,;.rW>i~'it~~~j~~;(i~·:&i~£jl;(!''Mi~jiY:~
~-AMYLOID

l

j

RESULTS

A.dherence of Cortical Neurons to (3-Amyloid

1 ~ To examine the interaction between substrate bound
) -amyloid and neurons, we first challenged neurons in
I Culture with immobilized synthetic peptides of the 39-
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saline. For the filter implants, brains were perfused with
{ the same fix and cryosectioned after which sections
were treated the same as cultures. Fixed cultures and
i sections were washed extensively with PBS and blocked
for 2 h with 0.1 % BSA/4% NGS in PBS. Cultures and
i sections were then exposed to a mixture of antibodies:
GFAP (Accurate Chemical, specific for glial acidic fi{ brillar protein) and CS-56, (ICN ImmunoBiologicals,
which recognizes chondroitin 6-sulfate-containing pro( teoglycans), optimally diluted in staining buffer (0.01 %
BSA/O.4% NGS in PBS containing 0.01% Tween 20).
After 1 h, the primary cocktail was washed away with
multiple changes of staining buffer and then exposed to
an optimally diluted mixture of biotinylated goat antimouse IgM and fluorescein-conjugated goat anti-rabbit
IgG in staining buffer. After incubation with secondary
cocktail, cultures were washed as before and incubated
with strepavidin-conjugated Texas Red (Amersham).
Cultures were rinsed and coverslipped in Citifluor (Citifluor Ltd.) and viewed on a Leitz Orthoplan 2 microscope fitted for phase-contrast, DIC, and fluorescence
optics. Control staining was carried out as follows. Cultures which had either or both primaries omitted in the
above protocol did not show any significant staining.
Likewise, peptide spots exposed to culture medium
alone for 14 days in the absence of cells stained negative
with CS-56. The presence of chondroitin sulfate proteoglycan in our cultures and filter implants was confirmed
with another monoclonal antibody, 3B3, which recognizes the sugar stubs of chondroitin-6-sulfate glycosaminoglycan side chains near the protein core of the proteoglycan after chondroitinase digestion.
For immunocytochemistry of AD tissue, human hippocampus and frontal cortex were obtained postmortem, fixed in Methacarn (MeOH, 60%; acetic acid, 10%;
chloroform, 30%), and embedded in paraffin wax.
1 Chondroitinase ABC, heparinase, or heparitinase were
applied to the sections overnight at 20°C in Tris-buf! fered saline (pH 7.6). Sections were processed for
immunostaining using the peroxidase-antiperoxidase
method, with 3,3,5,5-diaminobenzidine tetrahydrochloride as the substrate. The presence of GFAP-positive
1 astrocytes was visualized using polyclonal anti-GFAP
) with alkaline phosphatase-linked anti-rabbit IgG and
Fast Blue R (biotin-avidin). The 3B3 monoclonal anti1 body recognizes the sugar stubs of chondroitin-6-sulfate
glycosaminoglycan side chains near the protein core of
the proteoglycan after chondroitinase digestion.
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THE VALUES REPRESENT THE
RATIO OF NEURONS PER UNIT
AREA ON THE PEPTIDE SPOTS AS
COMPARED TO AN EOUIVALENT
AREA AWAY FROM THE SPOT
AFTER 48HRS IN CULTURE.
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FIG.!.

Density of cortical neurons on ~-amyloid peptide spots in

vitro. The values represent the ratio of neurons per unit area on the
peptide spots as compared to an equivalent area away from the spot
after 48 h in culture. Neurons preferentially adhere to the 1-40 and
25-35 ~-amyloid peptides over the surrounding laminin alone substrate (n = 18). With the scrambled 1-40 and 25-35 peptides, no cells
were observed to adhere to the spot when this peptide was used as a
substrate (n = 15). After conditioning by exposure to cortical glial
cells for 14 days, the 25-35 peptide spot showed a very much diminished ability to support neuron attachment (n = 21).

43 amino acid {3-amyloid molecule and followed their
responses using a plaque-like "spot" assay. Cortical neurons seeded onto spots of 1-40 or 25-35 {3-amyloid peptides showed a marked preferential adherence to the
peptide surface over the surrounding laminin substrate
(Figs. 1 and 3A). By contrast, cortical neurons seeded at
similar cell densities on the scrambled 1-40 or scrambled 25-35 peptides did not adhere at all. This suggested
that neuronal cells of the cortex have an adhesive affinity for the 1-40 amino acid sequence of the {3-amyloid
molecule, and that this affinity may be mediated by the
25-35 sequence of the {3-amyloid molecule.

Behavior of Cortical Glia on {3-Amyloid Substrates
When glial cells were seeded onto the 25-35, 1-40,
scrambled 25-35, or scrambled 1-40 amino acid peptides of the {3-amyloid molecule, they initially attached
and spread on all of the peptide surfaces showing no
preference for the peptide spots over the surrounding
laminin substrate. However, time-lapse videomicroscopy of the glial cultures on each of the nonscrambled
amyloid components showed that glial cells exhibit different behaviors on the peptide substrates compared to
cells off the peptide spots. Within a matter of hours,
cells resident on the peptide spots underwent a profound change in morphology by producing many elongated processes. In addition, the motility of cells on the
peptides dramatically increased relative to those seeded
away from the spot. During their time on the 25-35 and
1-40 peptides some cells showed alternating periods of
motility and quiescence. However, even during the stationary phase, these cells showed a pronounced ruffling
of the cell surface not shown by cells off the spots. Glial
cells traversed the border on and off the peptide sub-
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FIG. 2. Change in relative glial cell density on .a-amyloid peptide spots in vitro. Each bar represents an equivalent number of cells.
Changes in the ratio of cells on the peptide spot to regions away from the spot per unit area are shown by the intersection with the abscissa. On
the 1-40 and 25-35 peptide spots, cells remain resident for many days but gradually the density on these peptides declines at comparable rates
(n = 46). Cells on the scrambled 1-40 and 25-35 peptide spots remain at similar densities as on the surrounding substrate (n = 12) ..

strate freely, indicating that the border of the peptide
was not a physical barrier to cell movements and that
the peptides were not inherently nonadhesive or repulsive to glial cells. Glial cells do not exhibit increased
motility or the same changes in morphology in preparations of scrambled 25-35 or scrambled 1-40 peptides.
With time, the density of glial cells on the 1-40 or 25-35
peptide substrate decreases relative to the cell density
off the spot (Fig. 2). This appears to occur by cells on the
peptide spots eventually wandering off the peptides
without returning. Cells left on these peptides sometimes form aggregates on the peptide surface which is
not seen by cells off the spots. Thus, time-lapse videomicroscopy revealed glial cells to have altered behavior,
in terms of cell movements and morphologies, on the
1-40 and 25-35 peptides. This seemingly "reactive" behavior on the 1-40 and 25-35 ,a-amyloid peptide spots
led us to examine the possibility that glial cells had initiated the deposition of gliotic scar components while in
contact with the ,a-amyloid peptides.

Cortical Glia Condition ,a-Amyloid Substrates by ECM
Deposition
After 14 days exposure of the 25-35 and 1-40 peptide
spots, glial cells were replaced with cortical neurons.
Unlike cortical neurons seeded directly onto unconditioned 25-35 and 1-40 peptides, cells now failed to show
an adhesive preference for the preconditioned spot,
with far fewer cells adhering to the spot than the
surrounding laminin substrate (Figs. 1 and 3B). Control
spots left in culture for the same time period but without
exposure to glial cells still permitted preferential neu-

ron adhesion. This indicated that the surface of the peptide spot exposed to glia had become an unfavorable
substrate to the attachment and growth of neurons as a
consequence of glial reactivity.
We therefore tested glial-conditioned 25-35 and 1-40
peptide spots for the presence of glycosaminoglycanbearing proteoglycans, an indicator of functionally
reactive gliotic scar formation after trauma (21). After 5
days in culture, chondroitin sulfate-containing proteoglycan deposition could be seen at points of cell contact
with the peptide (Fig. 4). The deposition of chondroitin
sulfate proteoglycan on the peptide spots increased with
longer exposures to glial cells (Fig. 5). Over the surface
of the peptide spots irregularly shaped, cell~sized
blotches of chondroitin sulfate-containing proteoglycan
were found (Fig. 5A) and the complete circumferences
of the 25-35 and 1-40 peptides were eventually "walled
off" by high amounts of chondroitin sulfate deposition
after 14 days in culture (Figs. 5B and 5C). Chondroitin
sulfate-containing proteoglycan was not deposited on
scrambled 1-40 and scrambled 25-35 peptides over com'
parable time periods. Thus, we propose that glial cells
become reactive when they are in contact with immobilized 1-40 and 25-35 peptides of the ,a-amyloid molecule
and that this reactivity is manifested by the local deposition of enhanced amounts of chondroitin sulfate-bearing proteoglycan. Since analysis of time-lapse films revealed no apparent difference in the rates of mitosis
between cells on the peptide spots and those off tlie
spots, this form of reactive gliosis is associated with a
large increase in cell motility but without any discernible increase in cell numbers.
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FIG. 3. Video prints of cortical neurons cultured on immobilized 25-35 ,6-amyloid peptides. (A) Cortical neurons 48 h postseeding on a 25-35
peptide spot. Relatively more neuronal processes and cell bodies are found on the peptide surface than away from the spot. (B) Cortical neurons 48 h
postseeding on a 25-35 peptide spot which had been previously exposed to mixed glia for 14 days. Unlike A, cells preferentially adhere to the
surrounding substrate rather than the conditioned peptide surface. Inset at low power magnification shows conditioned peptide surface to be largely
devoid of neuronal cells. Scale bars: A, 50 .um; B, 50 .um .
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FIG. 4.

295

Deposition of chondroitin sulfate-containing proteoglycan by cortical glial cells on {3-amyloid peptide spots in vitro. (A) A 25-35

~-amyloid peptide, (B) 1-40 {3-amyloid peptide sequence. Chondroitin sulfate positivity is shown in red and GFAP positivity is shown in

yellow-green. As cells approach the peptide spot from the side, chondroitin sulfate can be seen at the points of contact of the cells with the
peptide border (A, arrow). This becomes progressively more intense with time, as cells migrate along and over the edge of the peptide (B,
arrow). The bright green spots in A and B are fluorescent spheres endocytosed by glial cells used for tracking during timelapse videomicroSCOpy. Scale bars: A, 5 ~m; B, 10 ~m.
FIG. 5. Deposition of chondroitin sulfate-containing proteoglycan on immobilized 25-35 {3-amyloid peptide spots in vitro after 14 days
exposure to cortical glial cells. Chondroitin sulfate positivity is shown in red (A, B, and C) and GFAP positivity is shown in yellow-green (B and
C). (A) On the surface of the peptide after 14 days, localized areas of chondroitin sulfate deposition are left on the peptide surface showing that
the surface has been subjected to glial reactivity. The complete circumference of the peptide spot and much of the surface is coated with
chondroitin sulfate (B and C), areas which time-lapse videomicroscopy has shown to be repeatedly contacted by glial cells. The orange hue of
the peptide spots is an artifact of long camera exposures during fluorescence photography. Scale bars: A, 20 ~m; B, 100 ~m; C, 10 ~m.
FIG. 7. Immunolocalization of chondroitin sulfate proteoglycan in sections from cortex and hippocampus of patients diagnosed with
Alzheimer's disease. (A) Hippocampus: Chondroitin sulfate proteoglycan (brown) is found in intimate association with numerous. senile
Plaques (arrow). (B) Cortex: GFAP-positive astrocytes and astrocytic processes (purple-mauve stain; arrows) are located near the periphery of
~enile plaques (brown stain). Scale bars: A, 50 ~m; B, 25 ~m; C, 10 ~m. (C) Hippocampus: Higher magnification of a solitary senile plaque
Illllllunostained with monoclonal3B3 and Congo red. Birefringence of Congo red identifies the {3-amyloid core as the cross-shaped structure in
the center of the plaque. Chondroitin sulfate proteoglycan is located primarily around the periphery (brown).
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FIG. 6. Reactive gliosis to nitrocellulose filters saturated with J3-amyloid peptide implanted into the cortex of neonatal rats. GFAP
positivity is found at comparable levels in both the J3-amyloid-impregnated filter CA) and control filter CC), showing that glial cells infiltrate
both experimental and control filters. However, only the J3-amyloid-containing filter elicits a significant deposition of chondroitin sulfate CB),
which stains more intensely than the control filter without J3-amyloid CD). Scale bars: A, 500 I-'m; B, 800 I-'m; C, 500 I-'m; D, 800 I-'m.

In Vivo Response to Immobilized fJ-Amyloid
We then examined whether chondroitin sulfate proteo glycan is also deposited in excess in response to the
presence of fJ-amyloid in intact tissue. Neonatal rats,
which do not form chondroitin sulfate-containing scars
after lesions to the cortex (21), were implanted with nitrocellulose filters impregnated with 1-40 fJ-amyloid
and allowed to survive 30 days (21, 22). Approximately
the same number of GFAP-positive processes and cells
were seen infiltrating control and fJ-amyloid implants
(Figs. 6A and 6C). However, fJ-amyloid filters contained
significant amounts of chondroitin sulfate-containing
proteoglycan while comparable control filters revealed
little or no staining (Figs. 6B and 6D). Thus, glial cells in
intact living tissue react to the presence of fJ-amyloid by
producing chondroitin sulfate-bearing proteoglycan in a
manner similar to glia confronted with fJ-amyloid in

vitro.

effects of trauma, prompted us to search in human tissue for the association of chondroitin sulfate proteoglycan with senile plaques in AD patients. Using antibodies
against various glycosaminoglycan portions of chondroitin sulfate proteoglycan, we found greatly enhanced
amounts of chondroitin sulfate proteoglycan at the periphery of senile plaque cores (Fig. 7). Bearing some
similarity to our in vivo filter implants, the proteoglycan
was found to be associated with GFAP-positive astrocytes in the near vicinity of senile plaques (Fig. 7C).
Importantly, this distribution of chondroitin sulfate proteo glycan corresponds closely to the region around senile plaques which has both a decline in neuritic density
and an increase ofaxons exhibiting AD-associated cytoskeletal damage (2). Therefore, it appears likely that the
same events of reactive gliosis and deposition of chondroitin sulfate proteoglycan are taking place in the AD
brain as in our in vitro and in vivo models.

Chondroitin Sulfate Proteoglycan in Human AD Tissue

DISCUSSION

The finding that fJ-amyloid peptides induce enhanced
deposition of chondroitin sulfate proteoglycan in the
cortex ofliving rats, even when removed from the direct

Our study has focused on the possibility that neuritic
retraction and/or neuronal dystrophy associated with
Alzheimer-like plaques is not simply a consequence of
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direct neurotoxicity by ,B-amyloid (as it has been suggested in solution (15, 20, 34-36) or as insoluble peptide
aggregates (8, 24), but also of secondary glial cell reactions to the insoluble molecule. The ,B-amyloid peptides
I were bound to a substrate in our experimental model
systems and, therefore, it may be argued that this presentation of ,B-amyloid peptides to cortical cells more
closely mimics the situation of AD plaques in vivo where
p-amyloid is present in fibrillar form. We have shown
for the first time that ,B-am~loid peptide ~s able to ~nduce
I glial cells to become functlOnally reactIve both m cul~ ture and in the intact animal in that they specifically
deposit enhanced quantities of chondroitin-6-sulfate
proteoglycan, a known inhibitor of neuronal regeneration found in glial scars. We propose that the chondroitin sulfate proteoglycan present around senile plaques
of patients with AD, perhaps along with other proteoglycans previously described in association with senile
plaques (8, 24, 29-31), may be a link in the chain of
events that ultimately leads to neuronal dystrophy and
possibly neuronal loss.
The distinguishing feature by which ,B-amyloid is able
to act as an inducer of reactive gliosis is an especially
important but perplexing problem in light of the recent
observation that the ubiquitiously distributed (33) amyloid precursor protein (APP), from which ,B-amyloid is
abherrantly cleaved, may itself be a chondroitin sulfatebearing proteoglycan core protein (27). If this were the
case, then deposition of APP by a variety of injured cells
of which there is some evidence (14, 28) could be a global
initiator of scar formation in the CNS if the molecule
were fragmented and modified extracellularly (by microglia or reactive astrocytes (1)), perhaps in response
to the abnormal presence of a proteoglycan core protein. In this way, ,B-amyloid could be considered to be a
molecular trigger of gliosis among other candidate molecules such as cytokines and growth factors (11, 17). It
remains to be determined whether gliosis triggered by
~-amyloid results in the deposition of a variety of scarassociated molecules including different species of proteoglycans along with other extracellular matrix moleCUles such as tenascin (21). In the AD brain, such a process may explain why plaque-associated axonal damage
extends out and away from the dense ,B-amyloid core (2)
into the reactive astroglial areas and why characteristic
neuritic dystrophy occurs specifically in response to ,BamYloid deposition (3). Furthermore, our findings that
~-amyloid supports neuronal attachment, perhaps via
Some modification of laminin (16), unless conditioned
?yglia suggests that the extracellular matrix surroundlUg plaques could curtail neurite regeneration in the AD
.brain. Given the potent inhibitory nature of certain proteoglycans to neuronal cells, especially the inhibition by
tyPes of chondroitin-6-sulfate proteoglycan (32), this
Would suggest that glia can play important roles not
Only in the creation of axonal boundaries during normal

j

development, but also in the pathology of CNS lesions
and neurodegenerative disorders such as Alzheimer's
disease.
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